Related Articles
Comparison of the characteristics of uncommon epidermal growth factor receptor (EGFR) mutations and EGFR‑tyrosine kinase inhibitor treatment in patients with non‑small cell lung cancer from different ethnic groups
Patients with non‑small cell lung cancer with the exon 21 L858R mutation: From distinct mechanisms to epidermal growth factor receptor tyrosine kinase inhibitor treatments (Review)
Cotargeting EGFR and autophagy signaling: A novel therapeutic strategy for non‑small‑cell lung cancer (Review)
EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature
Osimertinib treatment response in a patient with lung adenocarcinoma harboring two rare EGFR mutations: A case report